Increasing Prevalence Of Urinary Stones Around The Globe Has Fueled The Growth Of The Urolithiasis Management Devices Market
Urolithiasis management devices are used to treat urinary tract infections and more. The main aim of these products is to promote healthy and rapid healing for the patients, by providing soothing relief to the affected areas, and preventing further damage to the patient. The main cause of this disease is a bacterial infection called Urtica dioica, which affects the large intestine of the body. This disease is extremely painful and may also affect other organs of the body.
The
growing prevalence and incidence of urinary stones is a prime factor driving
the growth of the urolithiasis management devices market. According to the
World Health Organization, the prevalence of upper urinary tract stones (renal
and ureteric) was high in both children (33/39, 84.6%) and adults (117/145,
80.7%). In adults, there was a higher prevalence of bladder stones in males
(15.2%) than in females (2.1%), a ratio of 7.2:1. Also, increasing preferences
for non-invasive surgeries are again projected to foster the growth of the
urolithiasis management devices market. The invention of non-invasive
techniques has also given rise to new treatments like urolithiasis management
devices, that can help reduce or eliminate this disease completely, without any
complications. The increasing geriatric population coupled with the advancement
in technology is further projected to augment the market growth.
North
America is projected to gain significant growth over the forecast period and
this is attributed to the increasing healthcare spending by the regional
government. According to the U.S. Centers for Medicare & Medicaid Services,
the U.S. health care spending grew 4.6 percent in 2019, reaching $3.8 trillion
or $11,582 per person. As a share of the
nation's Gross Domestic Product, health spending accounted for 17.7 percent. Also,
there is a high prevalence rate of urinary stones in the region which is again
driving the regional market growth.
Key Developments:
1. In September 2019, Dornier
MedTech (Dornier), a global urology company in kidney stone management,
launched the new OptiVision technology for the Dornier Delta® III at the German
Urology Congress (DGU) 2019 in Hamburg from 18-20 September 2019.
2. In September 2018, Boston
Scientific Corporation announced the global launch of the LithoVue Empower™
Retrieval Deployment Device, designed to be used with the LithoVue™ Single-Use
Digital Flexible Ureteroscope and compatible nitinol retrieval basket to enable
urologists to operate an ureteroscope and basket simultaneously when retrieving
kidney stones via flexible ureteroscopy (URS).
3. In June 2020, Olympus has
launched a new laser platform intended for soft tissue applications and for
lithotripsy, the destruction of hard masses within the body including in
particular kidney stones.
Comments
Post a Comment